| The coming decade in precision oncology: six riddles A Wahida, L Buschhorn, S Fröhling, PJ Jost, A Schneeweiss, P Lichter, ... Nature Reviews Cancer 23 (1), 43-54, 2023 | 86 | 2023 |
| Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose S Jilg, RT Hauch, J Kauschinger, L Buschhorn, TO Odinius, V Dill, ... Experimental hematology & oncology 8 (1), 9, 2019 | 49 | 2019 |
| Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications MA Gouda, BE Nelson, L Buschhorn, A Wahida, V Subbiah Clinical Cancer Research 29 (15), 2753-2760, 2023 | 29 | 2023 |
| N-of-1 trials in cancer drug development MA Gouda, L Buschhorn, A Schneeweiss, A Wahida, V Subbiah Cancer discovery 13 (6), 1301-1309, 2023 | 13 | 2023 |
| Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST) MA Gouda, F Janku, A Wahida, L Buschhorn, A Schneeweiss, NA Karim, ... Annals of Oncology, 2023 | 12 | 2023 |
| Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis V Dill, J Kauschinger, RT Hauch, L Buschhorn, TO Odinius, ... European Journal of Haematology 104 (2), 125-137, 2020 | 7 | 2020 |
| COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy C Pixberg, M Zapatka, M Hlevnjak, S Benedetto, JP Suppelna, J Heil, ... ESMO open 7 (6), 100637, 2022 | 5 | 2022 |
| Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies TO Odinius, L Buschhorn, C Wagner, RT Hauch, V Dill, M Dechant, ... Journal of cancer research and clinical oncology, 1-10, 2021 | 5 | 2021 |
| Reimbursement in the context of precision oncology approaches in metastatic breast cancer: challenges and experiences C Pixberg, M Schulze, L Buschhorn, JP Suppelna, A Mock, M Hlevnjak, ... Breast care, 1-8, 2023 | 2 | 2023 |
| Liquid biopsies and those three little words: finding the perfect match for the MTB A Wahida, L Buschhorn Medizinische Genetik 35 (4), 269-273, 2023 | 1 | 2023 |
| Breast-like cancer of unknown primary A Schneeweiss, L Buschhorn Die Radiologie, 1-5, 2023 | 1 | 2023 |
| Abstract PO1-19-05: COGNITION/-GUIDE–Implementation of Precision Oncology in Early High-Risk Breast Cancer V Thewes, L Strassl, M Zapatka, M Hlevnjak, C Pixberg, C Maurer, ... Cancer Research 84 (9_Supplement), PO1-19-05-PO1-19-05, 2024 | | 2024 |
| Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors K Kairemo, MA Gouda, L Buschhorn, A Wahida, HA Macapinlac, ... ESMO open 8 (4), 101575, 2023 | | 2023 |
| PIK3CA mutations predict PFS benefit in mTNBC patients treated with capecitabine L Buschhorn, M Schulze, M Zapatka, M Hlevnjak, S Heublein, C Fremd, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 20 (02), 0001, 2023 | | 2023 |
| HER2 based subtyping of metastatic breast cancer: clinical and molecular characteristics S Heublein, M Zapatka, M Hlevnjak, L Michel, K Smetanay, C Fremd, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 20 (02), 0016, 2023 | | 2023 |
| „Breast-like cancer of unknown primary": Implikationen für die radiologische Diagnostik. A Schneeweiss, L Buschhorn Die Radiologie 63 (5), 2023 | | 2023 |
| Elevated RIPK3 correlates with disease burden in myelofibrosis V Dill, CV Wagner, EC Keller, FJ Fernandez-Hernandez, K Shoumariyeh, ... Blood Advances 7 (7), 1219-1224, 2023 | | 2023 |
| Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications … MA Gouda, BE Nelson, L Buschhorn, A Wahida, V Subbiah Cancer Research 83 (7_Supplement), 1173-1173, 2023 | | 2023 |
| RIPK3-dependent necroinflammation as a disease promoting mechanism in human myelofibrosis V Dill, C Wagner, E Keller, K Shoumariyeh, T Odinius, L Buschhorn, ... | | 2021 |
| Transcriptomic profiling does dot refine mastocytosis diagnosis L Buschhorn, DI Odoni, J Geuder, TO Odinius, CV Wagner, S Jilg, ... Haematologica, 2020 | | 2020 |
Adam Wahida, M.D.-Ph.D.Institute of Metabolism and Cell Death, Helmholtz Zentrum München在 helmholtz-munich.de 的电子邮件经过验证
